| Darolutamide in nonmetastatic, castration-resistant prostate cancer K Fizazi, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... New England Journal of Medicine 380 (13), 1235-1246, 2019 | 902 | 2019 |
| Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep E Huupponen, A Maksimow, P Lapinlampi, M Särkelä, A Saastamoinen, ... Acta Anaesthesiologica Scandinavica 52 (2), 289-294, 2008 | 435 | 2008 |
| Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide K Fizazi, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... New England Journal of Medicine 383 (11), 1040-1049, 2020 | 317 | 2020 |
| Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects A Snapir, J Posti, E Kentala, J Koskenvuo, J Sundell, H Tuunanen, ... The Journal of the American Society of Anesthesiologists 105 (5), 902-910, 2006 | 200 | 2006 |
| An insertion/deletion polymorphism in the α2b-adrenergic receptor gene is a novel genetic risk factor for acute coronary events A Snapir, P Heinonen, TP Tuomainen, P Alhopuro, MK Karvonen, ... Journal of the American College of Cardiology 37 (6), 1516-1522, 2001 | 163 | 2001 |
| Variation in the alpha2B-adrenoceptorgene as a risk factor for prehospitalfatal myocardial infarction and sudden cardiac death A Snapir, J Mikkelsson, M Perola, A Penttilä, M Scheinin, PJ Karhunen Journal of the American College of Cardiology 41 (2), 190-194, 2003 | 145 | 2003 |
| Effects of common polymorphisms in the α1A-, α2B-, β1-and β2-adrenoreceptors on haemodynamic responses to adrenaline A Snapir, J Koskenvuo, J Toikka, M Orho-Melander, S Hinkka, M Saraste, ... Clinical Science 104 (5), 509-520, 2003 | 98 | 2003 |
| G-protein β3 subunit C825T polymorphism: no association with risk for hypertension and obesity A Snapir, P Heinonen, TP Tuomainen, TA Lakka, J Kauhanen, ... Journal of hypertension 19 (12), 2149-2155, 2001 | 73 | 2001 |
| First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours M Ameratunga, I Braña, P Bono, S Postel-Vinay, R Plummer, J Aspegren, ... British journal of cancer 123 (12), 1730-1736, 2020 | 69 | 2020 |
| Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study C Massard, HM Penttinen, E Vjaters, P Bono, V Lietuvietis, TL Tammela, ... European Urology 69 (5), 834-840, 2016 | 66 | 2016 |
| Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception M Hughes, A Snapir, J Wilkinson, D Snapir, FM Wigley, AL Herrick Rheumatology 54 (8), 1443-1447, 2015 | 63 | 2015 |
| Assessing the depth of dexmedetomidine‐induced sedation with electroencephalogram (EEG)‐based spectral entropy A Maksimow, A Snapir, M Särkelä, E Kentala, J Koskenvuo, J Posti, ... Acta anaesthesiologica scandinavica 51 (1), 22-30, 2007 | 61 | 2007 |
| Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate … K Fizazi, ND Shore, T Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... Journal of Clinical Oncology 38 (15_suppl), 5514-5514, 2020 | 58 | 2020 |
| Prospective–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group SD Patterson, N Cohen, M Karnoub, SL Truter, E Emison, ... Pharmacogenomics 12 (7), 939-951, 2011 | 49 | 2011 |
| Effects of nitric oxide synthase inhibition on dexmedetomidine-induced vasoconstriction in healthy human volunteers A Snapir, P Talke, J Posti, M Huiku, E Kentala, M Scheinin British journal of anaesthesia 102 (1), 38-46, 2009 | 45 | 2009 |
| The insertion/deletion variation in the α2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in … A Snapir, M Scheinin, LC Groop, M Orho-Melander Cardiovascular Diabetology 2, 1-6, 2003 | 43 | 2003 |
| Effect of α2B-Adrenoceptor Polymorphism on Peripheral Vasoconstriction in Healthy Volunteers P Talke, C Stapelfeldt, E Lobo, R Brown, M Scheinin, A Snapir The Journal of the American Society of Anesthesiologists 102 (3), 536-542, 2005 | 41 | 2005 |
| A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in … AL Herrick, AK Murray, A Ruck, J Rouru, TL Moore, J Whiteside, ... Rheumatology 53 (5), 948-952, 2014 | 38 | 2014 |
| Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial MR Smith, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, ... European Journal of Cancer 154, 138-146, 2021 | 36 | 2021 |
| Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group AW Warner, A Bhathena, S Gilardi, D Mohr, D Leong, KL Bienfait, ... Clinical Pharmacology & Therapeutics 89 (4), 529-536, 2011 | 33 | 2011 |
